Research
Hormonal
The FDA has approved GLP-1R agonists, liraglutide and semaglutide, for the management of obesity.
Practitioners can consider GLP-1R agonists as viable pharmacological options for obesity management.
StrongSupportsmedium confidence
However, with FDA approval of the glucagon-like peptide 1 receptor (GLP-1R) agonists, liraglutide and semaglutide, for the management of obesity, it is hoped the tide is beginning to turn.
Why this rating
The claim is based on regulatory approval, indicating a high level of evidence.
Source
Is polypharmacy the future for pharmacological management of obesity?
Ryan A. Lafferty et al. · Current Opinion in Endocrine and Metabolic Research · 2022
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →